Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin Alfa in Active Rheumatoid Arthritis
NCT03410056Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2018
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 2 trial of efavaleukin alfa in rheumatoid arthritis (RA), sponsored by Amgen. Started May 2018; status: terminated.
02
Drugs
efavaleukin alfa
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03410056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410056.